ReviewJournal of neuroinflammation2025
Nanozymes in neuropathic pain: strategies bridging oxidative stress, mitochondrial repair, and neuroimmune modulation for targeted therapy.
Review in Journal of neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Nanozyme-based therapeutic strategies for traumatic brain injury.International journal of pharmaceutics: X · 2026Review
- From neuroinflammation to immune reprogramming: Nanozyme-Integrated nanoplatforms for neuroimmune modulation in Parkinson's disease.Materials today. Bio · 2026Article
- Microtubule Cytoskeleton Dysfunction in Chronic Pain: Mechanisms of Transport Failure and Emerging Therapeutic Targets.International journal of molecular sciences · 2026Review
- Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Chronic Pain.Brain sciences · 2026Review
- 7-Hydroxyflavone mitigates partial sciatic nerve ligation-induced neuropathic pain via modulation of oxidative and inflammatory pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Elucidating the multitarget neuroprotective mechanisms of protocatechuic acid in neurological disorders (Review).Molecular medicine reports · 2026Review
- Unveiling the antioxidant and anti-epileptic potential ofRSC advances · 2026Article
- A synergistic nanozyme platform breaking the neuroinflammatory-oxidative stress cycle for extended pain relief.International journal of pharmaceutics: X · 2026Article
- Recent advances in nanomaterial-based strategies for chronic pain alleviation.Materials today. Bio · 2026Review
- Immune-cell-guided nanozymes: redefining targeted therapy for neuroinflammation in multiple sclerosis.Annals of medicine and surgery (2012) · 2026Article
- Talin1 loss activates DRG neurons to accelerate bone remodeling and fracture healing in mice.Journal of orthopaedic translation · 2026Article
- Augmenting the catalytic activity of ADzymes: strategic engineering from atomic structure design to macro-environmental interaction for enhanced biomedical efficacy.Journal of nanobiotechnology · 2026Review
- Neuroprotective Effects of Cerium Oxide Nanoparticles During Spaceflight.Small science · 2026Article
- Injectable Chondroitin Sulfate Methacrylate Hydrogel Microspheres Co-Loaded with GLPM Nanozyme, Dexamethasone, and Stem Cells for Synergistic Osteoarthritis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A Surface-Engineered Cerium Oxide Nanozyme Functionalized with L-Theanine for Redox and Inflammatory Modulation in Neuropathic Pain.International journal of nanomedicine · 2026Article
- Advances in basic research on post-cardiac arrest syndrome in adults: a comprehensive review.Frontiers in medicine · 2026Review
- Metabolite-neuro-immune relay in chronic pain: spatial-temporal lactate, succinate and itaconate signalling as drivers of glial reprogramming and neuronal sensitisation.Frontiers in pharmacology · 2026Review
- Thermodynamic Biomarkers of Neuroinflammation: Nanothermometry, Energy-Stress Dynamics, and Predictive Entropy in Glial-Vascular Networks.International journal of molecular sciences · 2025Review
- Enhancing peripheral nerve regeneration with rehabilitation and biomaterial-driven drug delivery strategies.Progress in biomedical engineering (Bristol, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Neuropathic pain is one of the most debilitating neurological conditions, significantly challenging to manage due to the complex interplay of oxidative stress, neuroinflammation, and mitochondrial dysfunction in its pathogenesis. Nanozyme (nanomaterials with enzyme-like activity) technology offers a promising strategy to tackle these multifaceted mechanisms. These nanozymes can scavenge reactive oxygen species (ROS), modulate inflammatory pathways, and reverse mitochondrial dysfunction, providing notable neuroprotection and pain relief for affected individuals. Additionally, nanozymes exhibit targeted delivery to the injury sites by using mechanisms such as lysosome-mediated endocytosis (e.g., SOD&Fe3O4@ZIF-8 nanozymes) and mannose receptor-mediated cellular uptake (e.g., mSPIONs nanozymes). Given the limitations of current treatment options, we underscore the advantages of nanozymes, including their multifunctional capabilities and potential to enhance therapeutic outcomes in pain management. This review focuses on the underlying mechanisms of neuropathic pain, particularly emphasizing the role of oxidative stress and its impact on disease progression. We examine the applications of nanozymes for treating neuropathic pain, highlighting their potential to scavenge ROS, relieve mitochondrial dysfunction, modulate neuroinflammatory pathways, and repair blood-spinal cord barrier integrity. Furthermore, this paper provides an overview of the current landscape of nanozyme research in neuropathic pain and future directions for their clinical translation in pain management, emphasizing their potential role in improving therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.